The mechanism responsible for the resistance of FLT3-ITD-expressing AML cells to FLT3-ITD antagonists is multifactorial and includes components such as additional mutations other than preexisting FLT3-ITD mutations and microenvironment-mediated resistance9,25. Here, FLT3 is linked to acute myeloid leukemia.